Bringing industry and medicine together in the battle against cancer, AREVA Med has announced another important milestone to continue this fight.
AREVA Med, an AREVA subsidiary, is dedicated to developing medical grade lead-212 isotopes to be used in promising Radioimmunotherapy. Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments.
In nuclear medicine, the development of new treatments is dictated by isotope availability. By utilizing AREVA’s engineering and technical expertise, in March 2010, AREVA Med announced the construction of a Lead-212 industrial production plant that will allow the creation of new targeted therapies for patients.
Now, to support the project’s rapid development, AREVA Med has formed an Advisory Committee to provide strategic advice and scientific guidance in the field of Radioimmunotherapy.
The members of the AREVA Med Advisory Committee are:
- Darrell R. Fisher, Ph.D., Medical Physicist and Lead for the Isotope Sciences Program at Pacific Northwest National Laboratory, Richland, Wash.
- Olivier Rixe, M.D., Ph.D., Director of the Experimental Therapeutics Program at the University of Cincinnati, Cincinnati, Ohio
- Brenda M. Sandmaier M.D., Medical Oncologist at Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Wash.
- George Sgouros, Ph.D., Director of the Radiopharmaceutical Dosimetry Section, Johns Hopkins University, Baltimore, Md.
- Christine A. White, M.D., Medical Oncologist and Hematologist, who held several senior positions in the clinical development of the first radio-immunotherapy approved in the US and Europe.
Noting the importance of expert scientific guidance for this project, AREVA Med President and CEO Patrick Bourdet said, “I’m delighted and honored that our company is able to involve these world class scientists. This support demonstrates the quality of our work and strategy. It also illustrates the potential of Radioimmunotherapy using 212Pb to treat many types of cancer.”
Find out more information on this Committee and their expertise in this important medial field here (http://areva.com/EN/operations-3638/the-areva-med-advisory-committee.html).